Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBM-P002 Gene Therapy for Parkinson's Disease
NCT05822739Phase 1Completed
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Apr 2023
- Primary completion
- Oct 2025
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BBM-P002 in Parkinson's disease (PD), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Incidence of Adverse Events and Serious Adverse Events at 52 weeks. Started Apr 2023; status: completed.
02
Drugs
BBM-P002
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05822739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05822739.